www.fdanews.com/articles/114594-insmed-selling-boulder-facility-to-merck
Insmed Selling Boulder Facility to Merck
February 13, 2009
Insmed Inc. is selling its division focused on developing generic biotechnology drugs to pharmaceutical giant Merck for $130 million, the company announced.
Denver Business Journal
Denver Business Journal